Introduction Influenza neuraminidase (NA) is an important target for protective antibodies and therapeutic drugs against influenza viruses. Currently, influenza subunit vaccines focus on ...

Influenza B virus [Austria/1359417/2021 (B/Victoria lineage)] Hemagglutinin (HA) Protein, His Tag (Cat. No. HAE-V52H8) binding to RBCs (Rooster red blood cells) at a final concentration of 0.4688 ...

The virus family Orthomyxoviridae contains seven genera: Influenza A virus, Influenza B virus, Influenza C virus, Influenza D virus, Thogotovirus, Infectious Salmon Anemia (ISA) virus and ...

Here’s how it works. Vaccines for the 2024-2025 flu season do not contain the "Yamagata lineage" of influenza because this branch of the flu virus family tree hasn't been detected since 2020.

Due to the emergence of highly pathogenic and oseltamivir-resistant influenza viruses, there is an urgent need to develop new anti-influenza agents. Herein, five subseries of oseltamivir derivatives ...

The double-layered protein nanoparticle vaccine, which is constructed with a stabilized portion of the influenza virus (the hemagglutinin (HA) stalk), induces broadly reactive immune responses and ...

Influenza B viruses are sometimes the dominant circulating strains during influenza seasons, such as the 2019-20 U.S. flu season when influenza B caused more than 50 percent of the infections.

The difference between seasonal flu and pandemic flu is whether or not people have had a chance to build immunity to the virus through previous exposure. People are exposed to influenza viruses ...

Influenza virus hemagglutinin (HA) has been the primary target for influenza vaccine development. Broadly protective antibodies targeting conserved regions of the HA unlock the possibility of ...

The influenza B virus protein BM2 is a protein channel that acidifies the virus, helping it to release its genetic material into infected cells. The water in this channel plays a critical role in ...